HS
AVTX icon

HighVista Strategies’s Avalo Therapeutics AVTX Stock Holding History

HighVista Strategies’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.27M Buy
122,610
+63,988
+109% +$1.01M 0.52% 52
2026
Q1 		$875K Sell
58,622
-37,009
-39% -$579K 0.24% 123
2025
Q4 		$1.74M Buy
95,631
+67,853
+244% +$1.15M 0.45% 59
2025
Q3 		$353K Buy
+27,778
New +$239K 0.09% 143

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

HighVista Strategies's AVTX Position: Q2 2026 in Review

HighVista Strategies increased its Avalo Therapeutics (AVTX) stake by 109% in Q2 2026, buying an estimated $1.01M and bringing the position to 122,610 shares worth $2.27M. The position accounts for 0.52% of the portfolio, ranked #52.

HighVista Strategies first reported a position in AVTX in Q3 2025 and has held it in 4 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • HighVista Strategies held 122,610 shares of Avalo Therapeutics worth $2.27M as of Q2 2026.
  • HighVista Strategies bought 63,988 Avalo Therapeutics shares in Q2 2026, an estimated $1.01M.
  • Avalo Therapeutics made up 0.52% of HighVista Strategies's portfolio in Q2 2026, its #52 holding.
  • HighVista Strategies first reported a position in Avalo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.